---
title: "Tarsus Pharmaceuticals | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 173.91 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295098715.md"
datetime: "2026-08-06T11:24:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295098715.md)
  - [en](https://longbridge.com/en/news/295098715.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295098715.md)
generator: "portal-rs"
---

# Tarsus Pharmaceuticals | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 173.91 M

Revenue: As of FY2026 Q2, the actual value is USD 173.91 M, beating the estimate of USD 169.51 M.

EPS: As of FY2026 Q2, the actual value is USD -0.43, missing the estimate of USD -0.2.

EBIT: As of FY2026 Q2, the actual value is USD -21.45 M.

The provided reference, a Form 8-K filing from Tarsus Pharmaceuticals, Inc. dated August 6, 2026, indicates the company issued a press release detailing its results of operations for the three and six months ended June 30, 2026. However, the actual content of this press release, which would contain specific financial and operational metrics, as well as any outlook or guidance, is not included within the provided reference material. Consequently, no specific financial metrics, operational metrics, or outlook/guidance can be extracted directly from the given text .

### Related Stocks

- [TARS.US](https://longbridge.com/en/quote/TARS.US.md)

## Related News & Research

- [Wasatch Advisors LP Buys New Holdings in Tarsus Pharmaceuticals, Inc. $TARS](https://longbridge.com/en/news/295772808.md)
- [Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth | TARS Stock News](https://longbridge.com/en/news/295100037.md)
- [Apimeds Pharmaceuticals US Enters Assignment And Transfer Agreement With Freet On August 19](https://longbridge.com/en/news/296655292.md)
- [Great Lakes Advisors LLC Acquires Shares of 29,800 Supernus Pharmaceuticals, Inc. $SUPN](https://longbridge.com/en/news/296676820.md)
- [39,241 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Bought by GSA Capital Partners LLP](https://longbridge.com/en/news/296452266.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**